AVBP — ArriVent BioPharma, Inc. stock price, charts and financials

QT81ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
30.51
-0.33-1.07%
OverviewShort InterestFilings
AVBPQT81ArriVent BioPharma, Inc.·NASDAQ
30.51-1.07%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-Insider Own22.41%Shs Outstand46.57MPerf Week3.42%
Market Cap1.44BForward P/E-EPS next Y-3.42Insider Trans0.00%Shs Float29.78MPerf Month-8.41%
Enterprise Value1.37BPEG-EPS next Q-Inst Own-Short Float25.74%Perf Quarter6.90%
Income-150.10MP/S0.00EPS this Y-Inst Trans-Short Ratio14.13Perf Half Y44.45%
Sales0.00P/B4.29EPS next Y16.71%ROA-41.58%Short Interest7.67MPerf YTD53.28%
Book/sh-P/C-EPS next 5Y-ROE-48.98%52W High35.45 -13.93%Perf Year61.55%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-48.36%52W Low15.93 91.55%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.32% 6.54%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-35.55%Oper. Margin0.00%ATR (14)1.93Perf 10Y-
Dividend Ex-Date-Quick Ratio13.95Sales Y/Y TTM-Profit Margin0.00%RSI (14)48.40Recom2.00
Dividend Gr. 3/5Y-Current Ratio13.95EPS Q/Q49.47%SMA20-0.44%Beta1.17Target Price45.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-2.44%Rel Volume0.54Prev Close30.84
Employees77LT Debt/Eq-EarningsAug 14SMA20020.51%Avg Volume555.23KPrice30.51
IPO DateJan 26, 2024Option/ShortYes / YesEPS/Sales Surpr.-7.24% -Net Debt/EBITDA0.42Volume302,087Change-1.07%
Analyst Ratings
DateActionAnalystRatingTarget
May-29-26ReiteratedTruist SecuritiesBuy$43 → $45
Dec-10-25InitiatedBTIG on firmonertinib potentialBuy$45
Nov-25-25InitiatedTruistBuy$43
Jul-10-25ResumedGoldman SachsBuy$33
Sep-10-24ReiteratedHC Wainwright & Co.Buy$30 → $36
Aug-16-24ReiteratedHC Wainwright & Co.Buy$30
Jul-22-24ReiteratedOppenheimer$35
Latest News
Company

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue
000——
Cost of Goods Sold Incl. D&A
000——
Gross Profit
000——
Selling, General and Administrative Excl. Other241510——
Research and Development1537965——
Other Operating Expense100——
Operating Income-178-94-75——
Interest Expense
000——
Unusual Expense
—————
Non-Operating Income (Expense)11145——
Net Income Before Taxes-166-80-69——
Income Taxes
000——
Consolidated Net Income-166-80-69——
Net Income From Continuing Operations-166-80-69——
Net Income-166-80-69——
EPS (Recurring)-4.32-2.56-2.17——
EPS (Basic, Before Extraordinaries)-4.32-2.56-2.17——
EPS (Diluted)-4.32-2.56-2.17——
EBITDA-166-80-69——
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio
—————
Gross Margin
—————
Operating Margin
—————
Net Margin
—————
Shares Outstanding383132——
Market Capitalization765826———
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$37.41$31.63$25.85$20.06$14.28● Close Price0.00M3.25M6.49M9.74M12.98MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HILLHOUSE INVESTMENT MANAGEMENT, LTD.10% OwnerDec 10 '25Sale23.37555,55512,983,3203,929,117Feb 03
LaChapelle RobinChief Operating OfficerJul 11 '25Option Exercise2.2811,15325,429135,736Jul 15
LaChapelle RobinChief Operating OfficerSep 19 '24Option Exercise3.2827,56690,482124,583Sep 23
HILLHOUSE INVESTMENT MANAGEMENT, LTD.10% OwnerJan 30 '24Buy18.00555,5559,999,9904,484,672Feb 01
ORBIMED ADVISORS LLCdirector, 10 percent owner:Jan 30 '24Buy18.00222,2223,999,9961,513,664Jan 31
GORDON CARL Ldirector, 10 percent owner:Jan 30 '24Buy18.00222,2223,999,9961,513,664Jan 31
HEALY JAMESDirectorJan 30 '24Buy18.00444,4447,999,9921,696,752Jan 31
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.